Vir Biotechnology Inc
VIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.79B
Close$
$12.26
16% upside
Current Fair Value
16% upsideUndervalued by 16% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.79 Billion |
|---|---|
| Enterprise Value | $1.60 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.59 |
| Outstanding Shares | 167,719,015 |
Return
| Return on Equity | -25.62% |
|---|---|
| Return on Assets | -20.72% |
| Return on Invested Capital | -24.39% |
Valuation & Multiples
| P/E Ratio | -5.71 |
|---|---|
| PEG | 3.32 |
| Price to Sales | 10.57 |
| Price to Book Ratio | 2.11 |
| Enterprise Value to Revenue | 5.29 |
| Enterprise Value to EBIT | -5.87 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.33
Average shareholder expectationRevenue Estimate
$135.88 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.75
Average shareholder expectationRevenue Estimate
$956,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 54.13% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.16%▼ 88.04% |
|---|---|
| Total Invested | $2.97M▼ 99.80% |
| Investors Holding | 18▼ 228.00% |
ESG Score
No data
About Vir Biotechnology Inc
327 employeesVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...